Patent · US Active

Soluble heterodimeric CD94/NKG2 receptors fusion proteins

US7932055B2 · kind B2 · utility

6Cited by
4References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 22, 2007
Grant dateApr 26, 2011
Priority date
Expiry dateJun 22, 2027

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2333/70596
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.